phenylbenzimidazolesulfonic acid

Small moleculeexperimental

Clinical trial activity

2 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0

Earliest trial started Jul 1, 2008 (NCT00530387)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetUltraviolet filter

    ultraviolet filter

Chemistry & pharmacology

Loading structure…

SMILES

O=S(=O)(O)c1ccc2[nH]c(-c3ccccc3)nc2c1
Mol. weight
274.3 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 2-phenylbenzimidazole-5-sulfonic acid
  • 2-phenylbenzimidazole-5-sulfonic acid, monosodium salt
  • ensulizole
  • ensulizole
  • ensulizole
  • ensulizole
  • ensulizole
  • ensulizole
  • eusolex 232
  • eusolex 232
  • novantisol
  • phenylbenzimidazole sulfonic acid
  • phenylbenzimidazole sulfonic acid
  • phenylbenzimidazole sulfonic acid
  • phenylbenzimidazole sulfonic acid
  • phenylbenzimidazole sulfonic acid
  • phenylbenzimidazole sulfonic acid
  • phenylbenzimidazolesulfonic acid
  • phenylbenzimidazole sulphonic acid
  • phenylbenzimidazole sulphonic acid
  • phenylbenzimidazol sulfonic acid

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01001975Phase 3Jul 1, 2009Bayer
NCT00530387N/AJul 1, 2008University of Dundee
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
BayerFor profit1112009
University of DundeeAcademic/Hospital1112008
2 organizations
Page 1 / 1